Metabolic Code[®] KYOLIC[®]+

Supports Circulatory Function and Overall Heart Health*

- Clinical Strength, Odorless Formula
- Metabolic Code[®] Kyolic[®]+ formula blends clinically proven Kyolic[®] Aged Garlic Extract[™] and MegaNatural-BP[®] proprietary Grape Seed Extract to create a superior antioxidant supplement to optimize heart and vascular health.*
- **Metabolic Code® Kyolic®+** is odorless, GI friendly and meets nutrient standards for purity and potency, as well as overall product quality.

SUGGESTED USE: Take three caplets daily with a meal.

Supplement Facts Serving Size 3 caplets

Servings Per Container 30

| Servings i el container So | | |
|---|-----------------------|-----|
| | Amount per serving | %DV |
| Aged Garlic Extract ^{™++} Powder (bulb) | 2400 mg | ** |
| Grape Seed Extract (MegaNatural-BP [®]) | 300 mg | ** |
| **Daily Value (DV) not established | | |

**Special Garlic Preparation

Other ingredients: Microcrystalline cellulose, Organic Rice Extract Blend (Rice extract, rice hulls, gum arabic, sunflower oil), Croscarmellose Sodium, Hydroxypropylcellulose, Silicon Dioxide, Organic Coating (maltodextrin, sunflower lecithin, palm oil, guar gum), Carnuba Wax.

Free of: GMOs, soy, gluten, sugar, dairy, preservatives, artificial colors and flavors.

Warning: Consult your healthcare professional before using this or any product if you are pregnant, nursing, or under medical care.

Refrigeration not required. Store in a cool, dry place with cap tight.

Keep out of reach of children.

Safety Sealed: Do not use if safety band or inner seal is broken or missing.

MegaNatural-BP[®] is a registered trademark of E. & J. Gallo Winery.

Manufactured by: Wakunaga of America Co., Ltd. Mission Viejo, CA 92691 USA 800.421.2998 www.kyolic.com Distributed by:

Natural Formulations, LLC Cincinnati, OH 45202 USA www.metaboliccode.com

Product Code 502-69CX: 90 caplets

> *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

INTENDED FOR PROFESSIONAL USE ONLY



Metabolic Code[®] KYOLIC[®]+

Supports Circulatory Function and Overall Heart Health*

Metabolic Code[®] Kyolic[®]+ containing Aged Garlic Extract[™] (AGE) [2400 mg] and Grape Seed Extract (MegaNatural-BP[®]) [300 mg] per serving [3 caplets], is designed to support circulatory function and overall heart health.*

Aged Garlic Extract was shown in several clinical studies to support a healthy cardiovascular system by reducing the risk factors that cause atherosclerosis (e.g., coronary artery calcification^{1-3,15,16}, cholesterol^{13,21-}²⁶, homocysteine¹⁸, blood pressure^{9-12,17}, oxidative stress^{19,20}, vessel function and circulation^{4-8,27-29}).

MegaNatural-BP[®] is a grape seed extract standardized for total phenolics, gallic acid and the catechin and epicatechin content. One randomized, double-blind, placebo-controlled, parallel-group study showed that taking 300 mg daily of MegaNatural-BP tends to stabilize blood pressure in adults with normal and high blood pressure when consumed daily for 8 weeks¹⁴.

| | Subjects | Dose & Duration | Results [*] | Publication(s) |
|---------------------------------------|---|--|--|--|
| Coronary Artery Calcification | n=66 (Kyolic n=37; placebo n=29) Adults with type 2 diabetes mellitus | 2400 mg AGE powder daily for 1 year | Left ventricular myocardial mass 1.4% ↓ | 1. Hutchins E, et al. Exp Ther Med. 2020;19(2):1468-1471. |
| | n=66 (Kyolic n=37; placebo n=29) Adults with type 2 diabetes mellitus | 2400 mg AGE powder daily for 1 year | Low attenuation plaque 86%↓ | 2. Shaikh K, et al. Exp Ther Med. 2020;19(2):1457-1461. |
| | n=55 (Kyolic n=27; placebo n=28) Adults with metabolic syndrome | 2400 mg AGE powder daily for 1 year | Low attenuation plaque 20% ↓ | 3. Matsumoto S, et al. J Nutr. 2016;146(2):427S-432S. |
| Vascular Function & Circulation | n=28 With cardiovascular risk factors | 2400 mg AGE powder as a single administration | Upslope of tissue oxygen saturation (StO₂) ↑ Systolic blood pressure ↓ | 4. Leitão R, et al. Eur J Nutr. 2022;67(1):3357-3366. |
| | n=93 (Kyolic n=46; placebo n=47) Adults with glycated hemoglobin (HbA1c) < 8.0 and stable HbA1c level for 6 months, Framingham risk score > 10 and CAC score > 10 assessed with cardiac CT scan | 2400 mg AGE powder daily for 1 year | Post occlusive reactive hyperemia (PORH) 21.6% 个; cutaneous vascular conductance (CVC) 21.4% 个 | 5. Lindstedt S, et al. Int Wound J. 2021;18(5):681-691. |
| | n=88 (Kyolic n=44; placebo n=44) Patients with type 2 diabetes mellitus | 2400 mg AGE powder daily for 3 months | Cardio-ankle vascular index (CAVI) 8% ↓ | 6. Hamal S, et al. Exp Ther Med. 2020;19(2):1485-1489. |
| | n=122 (Kyolic n=60; placebo n=62) Framingham risk score ≥ 10 | 2400 mg AGE powder daily for 1 year | Cutaneous microcirculation 24% 个 | 7. Wlosinska M, et al. Int Wound J. 2019;16(6):1487-1493. |
| | • n=30 (Kyolic n=15; placebo n=15) | 2400 mg AGE powder daily for 2 weeks | Flow mediated dilation 44% 个 | 8. Williams MJA, et al. Phytother Res 2005;19(4):314-319. |

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

INTENDED FOR PROFESSIONAL USE ONLY

Metabolic Code[®] KYOLIC[®]+

Supports Circulatory Function and Overall Heart Health*

| Kyolic [®] Aged Garlic Extract [™] Clinical Studies | | | | |
|---|--|--|--|--|
| | Subjects | Dose & Duration | Results* | Publication(s) |
| Blood Pressure | n=49 (Kyolic n=23; placebo n=26) Patients with uncontrolled hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) | 1200 mg AGE powder daily for 12 weeks | Systolic 9% ↓ Diastolic 11% ↓ | 9. Ried K, et al. Front Nutr. 2018;5:122. |
| | n=88 Patients with uncontrolled hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) | 1200 mg AGE powder daily for 12 weeks | Systolic blood pressure 4% ↓ | 10. Ried K, et al. Integr Blood Press Control. 2016;9:9-21. |
| | n=79 (Kyolic 240 mg: n=21; 480 mg: n=20; 960 mg n=19; placebo n=19) Patients with uncontrolled hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) on antihypertensive medication | 240 mg, 480 mg, or 960 mg AGE powder daily for 12 weeks | Systolic blood pressure 8% ↓ (2 capsules) | 11. Ried K, et al. Eur J Clin Nutr. 2013;67(2):64-70. |
| | n=50 (Kyolic n=25; placebo n=25), SBP ≥ 140 n=22 (Kyolic n=12; placebo n=10) Patients with uncontrolled hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) on anti- hypertensive medication | 960 mg AGE powder daily for 12 weeks | Systolic blood pressure 6% ↓ | 12. Ried K, et al. Maturitas. 2010;67(2):144-150. |
| Oxidized LDL Cholesterol | n=9 (Kyolic n=3; raw garlic n=3; DL-α-tocopherol acetate n=3) | 2400 mg AGE powder daily for 1 week | Resistance to LDL oxidation 37% | 13. Munday JS, et al. Atherosclerosis 1999;143(3):399-404. |

| MegaNatural-BP [®] Grape Seed Extract | | | | |
|--|--|------------------|---|-------------------------------|
| | Subjects | Dose & | Results* | Publication(s) |
| | Subjects | Duration | | |
| Blood | n=70 (MegaNatural-BP n=35; | 300 mg GSE daily | Systolic 3 mmHg ↓ | 14. Ras RT, et al. Br J Nutr. |
| Pressure | placebo n=35) | for 8 weeks | Diastolic 1.4 mmHg↓ | 2013;110(12):2234-41. |
| | Adults with systolic blood pressure | | | |
| | between 120 and 159 mmHg | | | |

| Kyolic [®] Aged Garlic Extract™ Related Studies* | | |
|--|--|--|
| Coronary Artery Calcification 15. Budoff MJ, et al. Prev Med. 2004;39(5):985-91. 16. Budoff M. J Nutr. 2006;136(3 Suppl):741S-4S. <u>Blood Pressure</u> 17. Reid K, et al. Maturitas. 2010;67(2):144-50. <u>Homocysteine</u> 18. Weiss N, et al. J Nutr. 2006;136(3 Suppl):750S-4S. <u>Oxidative Stress</u> 19. Dillon SA, et al. J Nutr. 2002;132(2):167-71. 20. Kimoto R, et al. Hokkaido J Sports Med Sci. 2005;10:17-26. | <u>Cholesterol, Vessel Function and Circulation</u> 21. Lau BHS, et al. Nutr Res. 1987;7:139-49. 22. Steiner M, et al. Shiyaku to Rinsho (New Drug Clin). 1996;45(3):456-66. 23. Steiner M, et al. Am J Clin Nutr. 1996;64(6):866-70. 24. Yeh YY, et al. 1997. In: Food Factors for Cancer Prevention. Ohigashi H, Osawa T, et al. (eds). Springer-Verlag Tokyo, pp. 226-30. 25. Yeh YY and Liu L. J Nutr. 2001;131(35):9895-935. 26. Macan H, et al. J Nutr. 2006;136(3 Suppl):7935-55. 27. Okuhara T. Jpn Pharmacol Therapeut. 1994;22(8):3695-701. 28. Steiner M, Lin RS. J Cardiovasc Pharmacol. 1996;31(6):904-8. 29. Rahman K. Billington D. J Nutr. 2000;130(11):2662-5. | |

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

INTENDED FOR PROFESSIONAL USE ONLY